Myomo : Investor Presentation January 2022

Paul R. Gudonis, Chairman and CEO David Henry, CFO

Investor Presentation

Conquering Upper Limb Paralysis with Wearable Medical Robotics

January 2022

NYSE American: MYO

1

Legal Disclaimer

This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Company's financial position and projections of future operating results, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company's management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company's liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

NYSE American: MYO

2

Company Overview

We design, manufacture and provide the MyoPro™, a wearable medical robotic device that restores movement and function of paralyzed arms and hands

Lightweight and portable, to enable users to perform Activities of Daily Living

Only commercially available device of its kind with FDA registration, government and private reimbursement and CE mark

Can benefit patients suffering from

stroke, brachial plexus injury, traumatic brain or spinal cord injury, as well as ALS or other neuromuscular disease/injury

NYSE American: MYO

3

Investment Highlights: Market Leader in New Product Category

• Creating a new product category for this large unmet medical need
• • Patient Population with Chronic Arm Paralysis = Approx. 3M in US
  • New Incidences in US each year = Approx. 250K due to new strokes, other neuro conditions
  • Worldwide need: Prevalence = Approx. 1% of Population
• Experienced management team is rapidly scaling the only commercially-available device

to restore function for upper extremity paralysis

• • Growth rate of revenue is accelerating. 2020 Revenues up 98%; YTD 2021 revenue up 159% YoY
• Strong candidate pipeline growth in 2021 from ongoing rollout in US and International markets
• • Continued high number of insurance authorizations and orders in Q3 (133 units) and record Backlog = approx. $6.2M pending revenue
• Emphasizing our growing Direct Billing channel, resulting in higher ASPs and gross margin (75%)
• Cash position as of 9/30/21 = $12.6 million. Pro forma for warrant exercise transaction in October,

Cash = $17.4 million. Almost two years of cash at current burn rate.

NYSE American: MYO

4

Company Updates: January 2022

• Announced Progress on Insurance Reimbursement issue from November 2021
• • A major payer started to deny post-delivery payments on claims for pre-authorized units
  • 90% of these claims have now been paid, and others are in process
  • Payer has stated to us that they are working on an internal processing fix to avoid this issue in future
  • We continue to receive new Pre-Authorizations for their beneficiaries to receive a MyoPro
• Executed Amended China JV Agreement, Technology and Trademark Licenses

• • Next step is to receive $2.7M in license payments, then launch the JV with technology transfer and training of JV staff to manufacture and sell MyoPro units in China
• Announced MyoPro 2+ enhanced version of our current product line
• • Features 3D printing of orthotic components, digital scanning via telehealth call to measure patients, and migration to in-house fabrication and assembly
  • Lower production costs and reduced travel/personnel expenses with remote measurement

NYSE American: MYO

5